PDS Biotech (NASDAQ: $PDSB) is focused on the development & commercialization of T-cell stimulating immunotherapies based on the Versamune® platform.
Joined October 2019
- Tweets 531
- Following 103
- Followers 1,919
- Likes 55
259 Photos and videos
May 13
PDS Biotech will host a conference call and webcast today at 8:00 am ET to report financial results for the quarter and year ended March 31, 2026, and provide a clinical programs and corporate update. Join the webcast here: bit.ly/4wf8Gpo $PDSB
2
5
823
May 13
Frank Bedu-Addo, PhD, President and CEO of PDS Biotech, comments on the clinical and regulatory progress made in the first quarter 2026: bit.ly/4uCFTtw $PDSB
1
7
1,490
May 13
PDS Biotech today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. Read more: bit.ly/4uCFTtw $PDSB
5
1,471
May 6
PDS Biotech will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am ET. For details: bit.ly/4f5ulu4 $PDSB
1
2
1,069
Apr 23
April is #HeadAndNeckCancerAwarenessMonth. HPV is fueling a rise in these cancers, and patients deserve better treatment options. At PDS Biotech, we are seeking to deliver a novel and promising targeted immunotherapy for HPV16-driven head and neck cancers. Learn more: bit.ly/3X0FUsN
1
4
962
Apr 17
Head and neck cancers are expected to impact nearly 73,000 Americans this year, according to @theNCI. Early detection can save lives. Learn more about how to spot the symptoms from @CDCgov: bit.ly/3Ouls2k #HeadAndNeckCancerAwarenessMonth
6
1,036
Apr 15
Trials of PDS01ADC were performed in unresectable MSS or pMMR colorectal liver metasteses, which constitute the majority of mCRC, and in which immune checkpoint inhibitors have been unsuccessful. Read more on our positive Stage 1 interim Ph. 2 data: bit.ly/4ceHUWA $PDSB
1
3
10
1,432
Apr 15
PDS Biotech CEO Frank Bedu-Addo, PhD. comments on the positive PDS01ADC interim Phase 2 clinical trial data from Stage 1 of NCI-led metastatic colorectal cancer (mCRC) trial: bit.ly/4ceHUWA $PDSB
1
1
8
865
Apr 15
Recently published data in the Journal of Clinical Oncology (JCO) Oncology Advances highlights PDS01ADC's 78% objective response rate (ORR) and 2-year survival rate of >80%. Read more: bit.ly/4ceHUWA $PDSB
1
7
1,211
Apr 15
PDS Biotech today announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the March 10, 2026 issue of JCO Oncology Advances. Read more: bit.ly/4ceHUWA $PDSB
2
3
12
1,771
Mar 30
"The fourth quarter capped a year of important progress for PDS Biotech, marked by meaningful advances across our clinical programs, financial discipline, and intellectual property portfolio," said Frank Bedu-Addo, PhD, President and CEO. Read more: bit.ly/47vWE0o] $PDSB
2
6
2,189
Mar 30
PDS Biotech today provided a business and clinical programs update and reported financial results for the quarter and year ended December 31, 2025. Read the full clinical and corporate update: bit.ly/47vWE0o $PDSB
1
1
1,776
Mar 30
PDS Biotech will host a conference call and webcast today at 8:00 am ET to report financial results for the quarter and year ended December 31, 2025, and provide a clinical programs and corporate update. Join the webcast here: bit.ly/4uPPzl5 $PDSB
1
597
Mar 26
PDS Biotechnology CEO Frank Bedu-Addo discusses the Company's clinical progress and T-cell immunotherapy approach, as well as key trends across today's biotech environment in his interview with @pharmaboardroom. Read the full interview here: bit.ly/4teiC0p $PDSB
5
1
2,866
Mar 24
PDS Biotech will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30th at 8:00 am ET. For details, visit: bit.ly/4bvXA7p $PDSB
3
4
1,822
Mar 20
March is #ColorectalCancerAwarenessMonth – and colorectal cancer rates are rising. At PDS Biotech, we're dedicated to improving outcomes by transforming how the immune system targets and fights cancer to create targeted treatments. Learn more: bit.ly/4rMK30c
1
4
467
Mar 17
March is #NationalColorectalCancerAwarenessMonth. The incidence of early onset colorectal cancer is expected to increase by more than 140% by 2030 according to @AmericanCancer. Learn more about colorectal cancer here: bit.ly/3PGCESs
3
5
2,009
Feb 20
Frank Bedu-Addo, PhD, President and CEO, comments on the VERSATILE-003 Phase 3 protocol amendment to include PFS as an interim primary endpoint for potential accelerated approval of PDS0101 in HPV16-positive head and neck cancer: bit.ly/4kPqG4D $PDSB
2
2
6
2,093
Feb 20
The adoption of a protocol amendment in PDS Biotech's Phase 3 VERSATILE-003 clinical trial enables potential shorter time to accelerated approval of PDS0101 in HPV16-positive head and neck cancer. Read more about the amended protocol: bit.ly/4kPqG4D $PDSB
1
1
5
1,155
Feb 20
PDS Biotech today announced the adoption of a protocol amendment to its Ph. 3 VERSATILE-003 trial, including PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16 R/M head and neck cancer. bit.ly/4kPqG4D $PDSB
2
10
1,893